Literature DB >> 8785380

Influence of leucine on intestinal baclofen absorption as a model compound of neutral alpha-aminoacids.

T Cercós-Fortea1, A Polache, A Nácher, E Cejudo-Ferragud, V G Casabó, M Merino.   

Abstract

The inhibitory effect of the essential alpha-aminoacid L-leucine on the intestinal absorption of the antispastic drug baclofen was examined by means of an in situ rat gut perfusion technique. When 0.5 mM baclofen solutions were perfused in the presence of increasing concentrations of the aminoacid (5-100 mM), the apparent absorption rate constant of the drug decreased as the initial leucine concentration increased. Higher leucine concentrations however did not completely abolish the absorption of the drug (at 100 mM of leucine, only 76% inhibition was observed). The interaction can be mathematically described as a complete competitive inhibition with a second component, K = 0.35 (+/- 0.08)h-1, Ki = 0.25 (+/- 0.09)mM, AIC = -97.02. In the light of some of the absorption features of the drug, however, the residual absorption of baclofen in the presence of high leucine concentrations should be attributed to another transport system not used by leucine. Apparent parameters characterizing absorption of leucine in the presence of baclofen (0.5 mM) were Vm = 61.02 (+/- 5.46)mM h-1; Km = 8.04 (+/- 0.89)mM, and AIC = -62.25. The results indicate that baclofen and leucine share some carriers in the intestinal absorption processes. Since leucine is an essential dietary aminoacid, and therefore a normal food component, this finding could be relevant in preventing interactions that would lead to a reduced oral bioavailability during baclofen therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8785380     DOI: 10.1002/bdd.2510160705

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  6 in total

1.  Permeation and systemic absorption of R- and S-baclofen across the nasal mucosa.

Authors:  Hefei Zhang; Mark Schmidt; Daryl J Murry; Maureen D Donovan
Journal:  J Pharm Sci       Date:  2011-01-31       Impact factor: 3.534

Review 2.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

3.  Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.

Authors:  Yang He; Janice E Brunstrom-Hernandez; Liu Lin Thio; Shellie Lackey; Deborah Gaebler-Spira; Maxine M Kuroda; Elaine Stashinko; Alexander H Hoon; Jilda Vargus-Adams; Richard D Stevenson; Stephanie Lowenhaupt; John F McLaughlin; Ana Christensen; Nienke P Dosa; Maureen Butler; Aloysia Schwabe; Christina Lopez; Desiree Roge; Diane Kennedy; Ann Tilton; Linda E Krach; Andrew Lewandowski; Hongying Dai; Andrea Gaedigk; J Steven Leeder; William J Jusko
Journal:  J Pediatr       Date:  2014-03-05       Impact factor: 4.406

4.  Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats.

Authors:  N Ruiz-Balaguer; A Nacher; V G Casabo; M Merino
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy.

Authors:  Matthew J McLaughlin; Susan Abdel-Rahman; J Steven Leeder
Journal:  Curr Phys Med Rehabil Rep       Date:  2019-01-23

Review 6.  Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder.

Authors:  Nicolas Simon; Nicolas Franchitto; Benjamin Rolland
Journal:  Front Psychiatry       Date:  2018-10-05       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.